EAG预激化疗治疗老年急性髓系白血病30例

Clinical observation of EAG regimen in remission inductive treatment for elderly patients with acute myeloid leukemia

目的观察EAG预激化疗作为诱导缓解方案在治疗老年急性髓系白血病患者中的疗效。方法对应用EAG预激方案治疗的30例AML患者(≥60岁)的临床资料进行回顾性分析,包括完全缓解率、有效率、生存期以及不良反应。结果 EAG诱导缓解的有效率为70.0%(21/30),CR率为50.0%(15/30),中位无病生存期6.5个月;EAG预激化疗的主要不良反应为骨髓抑制期继发的感染、出血,调整方案后所有患者均能耐受。结论 EAG预激化疗作为诱导缓解方案适用于老年AML患者。

Objective To observe the efficacy of EAG regimen in remission inductive treatment for elderly patients with AML. Methods The clinical features of 30 cases with AML（ 1〉 60 years old） treated with EAG regimen in remission induction were retrospectively analyzed,including the CR rate,efficiency rate,surial as well as their toxicities. Results In 30 elderly patients with AML treated with EAG regimen,the efficiency rate was 70.0%（21/30）,CR rate was 50.0%（15/30）,the median disease-free surial was 6.5 months.The main toxicity of EA-G regimen was infections and bleeding secondary to hematopoiesis suppression after chemotherapy. All patients were well tolerated to adjusted regimen.Conclusion The EA-G regimen is much effective in remission induction for elderly t）atients with AML.